Superselective intraophthalmic artery chemotherapy (SSIOAC) has come to the forefront in the treatment of retinoblastoma, without the benefit of preclinical modeling.
1 Real-time ophthalmoscopic observations of SSIOAC in a nonhuman primate (NHP) model were described elsewhere.
2 Multiple acute ocular vascular sequelae were documented, including ophthalmic artery (OA) thrombosis, narrowing of the OA and retinal arteries, pulsatile optic nerve and retinal edema, retinal artery sheathing and precipitates, and choroid blanching and hypoperfusion.